Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jul 9;30(3):429-432.
doi: 10.18865/ed.30.3.429. eCollection 2020 Summer.

Impact of COVID-19 on Clinical Research and Inclusion of Diverse Populations

Daniel T Lackland  1 , Catrina Sims-Robinson  1 , Joy N Jones Buie  1 , Jenifer H Voeks  1
Affiliations
Editorial

Impact of COVID-19 on Clinical Research and Inclusion of Diverse Populations

Daniel T Lackland et al. Ethn Dis. .

Abstract

The randomized clinical trial (RCT) has long been recognized as the 'gold standard' for developing evidence for clinical treatments and vaccines; however, the successful implementation and translation of these findings is predicated upon external validity. The generalization of RCT findings are jeopardized by the lack of participation of at-risk groups such as African Americans, with long-recognized disproportional representation. Distinct factors that deter participation in RCTs include distrust, access, recruitment strategies, perceptions of research, and socioeconomic factors. While strategies have been implemented to improve external validity with greater participation among all segments of the population in RCTs, the coronavirus disease 2019 (COVID-19) pandemic may exacerbate disparities in RCT participation with the potential impact of delaying treatment development and vaccine interventions that are applicable and generalizable. Thus, it is essential to include diverse populations in such strategies and RCTs. This Perspective aims to direct attention to the additional harm from the pandemic as well as a refocus on the unresolved lack of inclusion of diverse populations in conducting RCTs.

Keywords: Clinical Research; Clinical Trials; External Validity; Underserved Minorities.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: None declared.

References

    1. Lackland DT, Woolson RF. Clinical hypertension research tools: the randomized controlled clinical trial. J Clin Hypertens (Greenwich). 2006;8(6):427-431. 10.1111/j.1524-6175.2006.04721.x - DOI - PMC - PubMed
    1. Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Contr. 2016;23(4):327-337. 10.1177/107327481602300404 - DOI - PMC - PubMed
    1. Crawley LM. African-American participation in clinical trials: situating trust and trustworthiness. J Natl Med Assoc. 2001;93(12)(suppl):14S-17S. - PMC - PubMed
    1. Newman LA, Roff NK, Weinberg AD. Cancer clinical trials accrual: missed opportunities to address disparities and missed opportunities to improve outcomes for all. Ann Surg Oncol. 2008;15(7):1818-1819. 10.1245/s10434-008-9869-2 - DOI - PMC - PubMed
    1. George S, Duran N, Norris K. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health. 2014;104(2):e16-e31. 10.2105/AJPH.2013.30170610.2105/AJPH.2013.301706 - DOI - DOI - PMC - PubMed

Publication types

LinkOut - more resources